Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and Harrington Discovery Institute  have formed an affiliation to advance therapies for rare diseases. The joint program combines capabilities to improve treatment options globally for patients with rare diseases.

The University of Oxford and University Hospitals in Cleveland, Ohio, have announced a multi-year affiliation to establish a global centre for rare diseases. The Oxford-Harrington Rare Disease Centre will bring together the capabilities, resources and expertise of both institutions to deliver new treatments for rare diseases, for which therapeutic options are lacking. Rare diseases affect 350 million people globally.

In this partnership, the University of Oxford and Harrington Discovery Institute commit to addressing unmet need in rare disease. Through our combined resources, the new Centre will set the science and innovation agenda to support cutting-edge breakthroughs across the UK and US with the greatest chance for clinical impact.

'Our partnership with Harrington Discovery Institute recognises the combined experience needed in world-class science and drug development if we are to change the rare disease landscape in a meaningful way – and Oxford is committed to doing so through this unique, open model supporting the most impactful innovation throughout the UK,' said Sir John Bell, Regius Professor of Medicine at Oxford.

Harrington UK Rare Disease Call - has now closed.

Funded projects will be announced in June 2020